High burden of cryptococcal antigenemia and meningitis among patients presenting at an emergency department in Maputo, Mozambique.
AIDS-Related Opportunistic Infections
/ epidemiology
Adult
Antigens, Fungal
/ immunology
Cryptococcosis
/ epidemiology
Cryptococcus
/ immunology
Emergency Service, Hospital
Female
HIV Infections
/ epidemiology
Humans
Male
Meningitis
/ diagnosis
Meningitis, Cryptococcal
/ diagnosis
Middle Aged
Mozambique
Prevalence
Retrospective Studies
Risk Factors
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
09
2020
accepted:
31
03
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
13
10
2021
Statut:
epublish
Résumé
Cryptococcal meningitis is a leading cause of HIV-related mortality in sub-Saharan Africa, however, screening for cryptococcal antigenemia has not been universally implemented. As a result, data concerning cryptococcal meningitis and antigenemia are sparse, and in Mozambique, the prevalence of both are unknown. We performed a retrospective analysis of routinely collected data from a point-of-care cryptococcal antigen screening program at a public hospital in Maputo, Mozambique. HIV-positive patients admitted to the emergency department underwent CD4 count testing; those with pre-defined abnormal vital signs or CD4 count ≤ 200 cells/μL received cryptococcal antigen testing and lumbar punctures if indicated. Patients with CM were admitted to the hospital and treated with liposomal amphotericin B and flucytosine; their 12-week outcomes were ascertained through review of medical records or telephone contact by program staff made in the routine course of service delivery. Among 1,795 patients screened for cryptococcal antigenemia between March 2018-March 2019, 134 (7.5%) were positive. Of patients with cryptococcal antigenemia, 96 (71.6%) were diagnosed with CM, representing 5.4% of all screened patients. Treatment outcomes were available for 87 CM patients: 24 patients (27.6%) died during induction treatment and 63 (72.4%) survived until discharge; of these, 38 (60.3%) remained in care, 9 (14.3%) died, and 16 (25.3%) were lost-to follow-up at 12 weeks. We found a high prevalence of cryptococcal antigenemia and meningitis among patients screened at an emergency department in Maputo, Mozambique. High mortality during and after induction therapy demonstrate missed opportunities for earlier detection of cryptococcal antigenemia, even as point-of-care screening and rapid assessment in an emergency room offer potential to improve outcomes.
Sections du résumé
BACKGROUND
Cryptococcal meningitis is a leading cause of HIV-related mortality in sub-Saharan Africa, however, screening for cryptococcal antigenemia has not been universally implemented. As a result, data concerning cryptococcal meningitis and antigenemia are sparse, and in Mozambique, the prevalence of both are unknown.
METHODS
We performed a retrospective analysis of routinely collected data from a point-of-care cryptococcal antigen screening program at a public hospital in Maputo, Mozambique. HIV-positive patients admitted to the emergency department underwent CD4 count testing; those with pre-defined abnormal vital signs or CD4 count ≤ 200 cells/μL received cryptococcal antigen testing and lumbar punctures if indicated. Patients with CM were admitted to the hospital and treated with liposomal amphotericin B and flucytosine; their 12-week outcomes were ascertained through review of medical records or telephone contact by program staff made in the routine course of service delivery.
RESULTS
Among 1,795 patients screened for cryptococcal antigenemia between March 2018-March 2019, 134 (7.5%) were positive. Of patients with cryptococcal antigenemia, 96 (71.6%) were diagnosed with CM, representing 5.4% of all screened patients. Treatment outcomes were available for 87 CM patients: 24 patients (27.6%) died during induction treatment and 63 (72.4%) survived until discharge; of these, 38 (60.3%) remained in care, 9 (14.3%) died, and 16 (25.3%) were lost-to follow-up at 12 weeks.
CONCLUSIONS
We found a high prevalence of cryptococcal antigenemia and meningitis among patients screened at an emergency department in Maputo, Mozambique. High mortality during and after induction therapy demonstrate missed opportunities for earlier detection of cryptococcal antigenemia, even as point-of-care screening and rapid assessment in an emergency room offer potential to improve outcomes.
Identifiants
pubmed: 33901215
doi: 10.1371/journal.pone.0250195
pii: PONE-D-20-29082
pmc: PMC8075188
doi:
Substances chimiques
Antigens, Fungal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250195Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Infect Dis. 2019 Apr;19(4):e143-e147
pubmed: 30344084
AIDS. 2015 Jan 2;29(1):67-76
pubmed: 25562492
PLoS One. 2017 Feb 24;12(2):e0171917
pubmed: 28234969
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159
pubmed: 29514236
Open Forum Infect Dis. 2018 Aug 29;5(8):ofy193
pubmed: 30182032
Clin Infect Dis. 2015 Mar 15;60(6):959-65
pubmed: 25422390
MMWR Morb Mortal Wkly Rep. 2017 Jun 02;66(21):558-563
pubmed: 28570507
BMC Infect Dis. 2018 Jan 30;18(1):59
pubmed: 29378523
PLoS One. 2013 Jul 19;8(7):e69288
pubmed: 23894442
PLoS One. 2013;8(3):e58377
pubmed: 23469276
J Neurosci Rural Pract. 2015 Apr-Jun;6(2):221-4
pubmed: 25883484
Open Forum Infect Dis. 2015 Apr 02;2(2):ofv046
pubmed: 26213690
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):117-21
pubmed: 27144527
Clin Infect Dis. 2010 Aug 15;51(4):448-55
pubmed: 20597693
Open Forum Infect Dis. 2016 Mar 15;3(2):ofw055
pubmed: 27186581
PLoS One. 2013 Apr 23;8(4):e62213
pubmed: 23626792
BMJ Open. 2018 Jul 30;8(7):e020654
pubmed: 30061436
Trop Med Int Health. 2016 Dec;21(12):1539-1544
pubmed: 27699970
Clin Infect Dis. 2019 Jan 18;68(3):393-401
pubmed: 29945252
Lancet. 2011 Oct 29;378(9802):1572-9
pubmed: 21951656
J Int Assoc Provid AIDS Care. 2016 Nov;15(6):505-511
pubmed: 25589304
PLoS One. 2009;4(5):e5575
pubmed: 19440326
Emerg Microbes Infect. 2017 Aug 23;6(8):e73
pubmed: 28831193
J Mycol Med. 2016 Dec;26(4):391-397
pubmed: 27641486
S Afr Med J. 2011 Apr;101(4):251-2
pubmed: 21786729
N Engl J Med. 2018 Mar 15;378(11):1004-1017
pubmed: 29539274
Lancet. 2015 May 30;385(9983):2173-82
pubmed: 25765698
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
MLO Med Lab Obs. 2013 Mar;45(3):16, 18, 20
pubmed: 23822028
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S126-S131
pubmed: 29514239
PLoS One. 2019 Dec 12;14(12):e0225742
pubmed: 31830060